<p>Phio Pharmaceuticals Corp. has announced the completion of enrollment in its Phase 1b clinical trial of PH-762, an INTASYL siRNA compound designed to silence the PD-1 gene implicated in various forms of skin cancer. The trial is evaluating the safety and tolerability of neoadjuvant intratumoral PH-762 in patients with cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. To date, 18 patients have completed treatment across five dose-escalating cohorts. Pathology results for the highest dose cohort are expected in Q1 2026. No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects have been observed so far. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 275716) on November 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

PHIO

<p>Phio Pharmaceuticals Corp. has completed enrollment in its Phase 1b clinical trial of PH-762, an siRNA compound targeting the PD-1 gene in skin cancer. The trial involves 18 patients with cSCC, melanoma, and Merkel cell carcinoma. No dose-limiting toxicities or significant adverse effects have been observed. Pathology results for the highest dose cohort are expected in Q1 2026.</p>

Phio Pharmaceuticals Completes Phase 1b Enrollment for PH-762 Skin Cancer Trial